Syncromune to Present at Piper Sandler 36th Annual Healthcare ConferenceFORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative first in class immunotherapies for solid tumors, today announced that Charles Link, M.D., Executive Chairman of Syncromune, will deliver...

Syncromune Granted FDA Fast-Track Designation for SYNC-T SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC)FORT LAUDERDALE, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has...

Syncromune® Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate CancerSYNC-T SV-102 Therapy combines partial tumor oncolysis with a fixed-dose combination multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic castrate-resistant prostate cancerSyncromune expects...

Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024Initial clinical data demonstrate a very high 85% overall response rate in patients with metastatic castrate-resistant prostate cancer.FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development...

Syncromune® Inc. to Present Initial Clinical Data from SYNC-T™ SV-102 Phase 1 as a Late-Breaker at the American Association for Cancer Research Annual Meeting 2024Presentation will take place during the “Cancer Vaccines: Ready for Prime Time?” session onApril 7, from 3:00 - 5:00pm PT at the San Diego Convention CenterMarch...